# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Elizabeth Anderson reinstates Quest Diagnostics (NYSE:DGX) with a In-Line and announces $165 pric...
Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:DGX) with a Equal-Weight and raises the price target from...
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Qu...
Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in OhioSECAUCUS, ...
Quest Diagnostics Incorporated (NYSE:DGX) (the "Company"), a leader in diagnostic information services, today announce...
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, dri...